Related Experiment Video
Updated: Apr 18, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Jae-Seung Yun1, Seung-Hyun Ko1
1Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The Korean Journal of Internal Medicine
|January 16, 2015
Summary
Severe hypoglycemia is a serious concern for type 2 diabetes patients, often caused by hypoglycemia-associated autonomic failure (HAAF). Individualized glycemic goals and careful patient selection are key to prevention.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Cardiovascular Health
Background:
- Hypoglycemia presents a significant obstacle to glycemic control in type 2 diabetes.
- Severe hypoglycemia, requiring external assistance, poses a life-threatening risk if not managed promptly.
- Hypoglycemia-associated autonomic failure (HAAF) is identified as the primary pathogenic mechanism for severe hypoglycemia.
Purpose of the Study:
- To highlight the clinical significance of severe hypoglycemia in type 2 diabetes.
- To discuss the pathogenic mechanisms, including HAAF and defective glucose counter-regulation.
- To emphasize the cardiovascular risks and quality of life impacts associated with hypoglycemia.
Main Methods:
- Review of evidence on hypoglycemia pathophysiology in type 2 diabetes.
- Analysis of hypoglycemia-associated autonomic failure (HAAF) components.
- Examination of hypoglycemia's role as a cardiovascular risk factor.
Main Results:
- Hypoglycemia-associated autonomic failure (HAAF) involves defective glucose counter-regulation and impaired hypoglycemia awareness.
- Evidence indicates hypoglycemia is an independent risk factor for cardiovascular disease.
- Hypoglycemia significantly impacts patients' quality of life.
Conclusions:
- Individualizing glycemic targets, especially for elderly or complex type 2 diabetes cases, is crucial for preventing hypoglycemic events.
- Careful identification of high-risk patients for severe hypoglycemia is necessary.
- Intensive, reinforced patient education is vital for effective hypoglycemia prevention strategies.
Keywords:
Diabetes educationHypoglycemia unawarenessHypoglycemia-associated autonomic failureSevere hypoglycemiaType 2 diabetesMore Related Videos
Related Concept Videos
01:26Hypoglycemia
2
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
2
01:15Hypoglycemia and Glucagon
1.4K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
01:22Diabetes Mellitus: Type 2 and Gestational
5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
999
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
999